Payment overview · 2025
General Payments
$584.85
28 reported records · 15 companies
Healthcare provider profile · identity verified
Solaiman Chowdhury
Allopathic & Osteopathic Physicians|Internal Medicine · EAST ISLIP, NY · NPI 1053763458
Verified facts
What the public records show
CMS Open Payments records show Solaiman Chowdhury received $584.85 in general payments during 2025 across 28 reported records.
Novo Nordisk Inc accounted for 29.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rexulti.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARANESP as an associated drug or biological on 16 records involving 13 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Aranesp by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Lokelma by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $171.17 | 29.3% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $71.20 | 12.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $55.34 | 9.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $36.87 | 6.3% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $34.10 | 5.8% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $28.45 | 4.9% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $25.78 | 4.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $25.12 | 4.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $25.11 | 4.3% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.40 | 4.2% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $22.42 | 3.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.66 | 3.4% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $16.09 | 2.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.42 | 2.6% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.72 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $584.85 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $91.74 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $79.43 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $72.99 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $71.20 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $55.34 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $53.76 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $36.87 | 2 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $28.45 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $28.45 | 1 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $25.78 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $25.12 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $25.12 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $25.11 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $24.40 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $22.42 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.42 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ARANESP open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 13 recipient NPIs · example record 1227128438 |
Aranesp · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 549 | 246 |
| Eliquis | Apixaban | 403 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 347 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 325 | 147 |
| Metoprolol Succinate | Metoprolol Succinate | 284 | 109 |
| Furosemide | Furosemide | 265 | 98 |
| Gabapentin | Gabapentin | 238 | 112 |
| Pantoprazole Sodium | Pantoprazole Sodium | 238 | 90 |
| Sertraline Hcl | Sertraline Hcl | 205 | 59 |
| Losartan Potassium | Losartan Potassium | 203 | 85 |
| Metformin Hcl | Metformin Hcl | 194 | 73 |
| Tamsulosin Hcl | Tamsulosin Hcl | 190 | 90 |
| Omeprazole | Omeprazole | 189 | 100 |
| Escitalopram Oxalate | Escitalopram Oxalate | 174 | 63 |
| Famotidine | Famotidine | 135 | 56 |
| Lisinopril | Lisinopril | 134 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 133 | 71 |
| Mirtazapine | Mirtazapine | 119 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 115 | 52 |
| Donepezil Hcl | Donepezil Hcl | 114 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 111 | 48 |
| Torsemide | Torsemide | 111 | 46 |
| Methylprednisolone | Methylprednisolone | 108 | 95 |
| Potassium Chloride | Potassium Chloride | 107 | 33 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 102 | 82 |
| Simvastatin | Simvastatin | 100 | 41 |
| Azithromycin | Azithromycin | 97 | 89 |
| Prednisone | Prednisone | 95 | 53 |
| Allopurinol | Allopurinol | 92 | 32 |
| Montelukast Sodium | Montelukast Sodium | 89 | 25 |
| Xarelto | Rivaroxaban | 87 | 19 |
| Carvedilol | Carvedilol | 82 | 38 |
| Memantine Hcl | Memantine Hcl | 82 | 19 |
| Spironolactone | Spironolactone | 81 | 35 |
| Enoxaparin Sodium | Enoxaparin Sodium | 76 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 70 | 53 |
| Hydralazine Hcl | Hydralazine Hcl | 68 | 38 |
| Sodium Chloride | 0.9 % Sodium Chloride | 68 | 30 |
| Finasteride | Finasteride | 67 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 52 |
| Trazodone Hcl | Trazodone Hcl | 65 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 63 | 30 |
| Alprazolam | Alprazolam | 62 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 22 |
| Levetiracetam | Levetiracetam | 53 | 17 |
| Glipizide | Glipizide | 52 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 50 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 33 |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 40 |
| Meloxicam | Meloxicam | 49 | 30 |
| Levofloxacin | Levofloxacin | 48 | 45 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 44 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 41 |
| Atenolol | Atenolol | 43 | 16 |
| Valsartan | Valsartan | 43 | 15 |
| Buspirone Hcl | Buspirone Hcl | 42 | 15 |
| Tramadol Hcl | Tramadol Hcl | 42 | 23 |
| Nystatin | Nystatin | 41 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | 17 |
| Rytary | Carbidopa/Levodopa | 38 | suppressed |
| Sucralfate | Sucralfate | 38 | 19 |
| Tradjenta | Linagliptin | 38 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 37 | 37 |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Baclofen | Baclofen | 36 | 13 |
| Nifedipine Er | Nifedipine | 36 | suppressed |
| Risperidone | Risperidone | 36 | 12 |
| Divalproex Sodium | Divalproex Sodium | 35 | 19 |
| Glimepiride | Glimepiride | 34 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | 21 |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Latanoprost | Latanoprost | 34 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 30 |
| Santyl | Collagenase Clostridium Hist. | 33 | 12 |
| Admelog | Insulin Lispro | 30 | suppressed |
| Dexamethasone | Dexamethasone | 30 | 11 |
| Lovastatin | Lovastatin | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 28 | 13 |
| Lactulose | Lactulose | 28 | 15 |
| Methocarbamol | Methocarbamol | 28 | 24 |
| Olanzapine | Olanzapine | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | 13 |
| Metformin Hcl Er | Metformin Hcl | 27 | 13 |
| Nuplazid | Pimavanserin Tartrate | 27 | suppressed |
| Primidone | Primidone | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Clonazepam | Clonazepam | 26 | 14 |
| Digoxin | Digoxin | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | 12 |
| Fluconazole | Fluconazole | 25 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | 14 |
| Midodrine Hcl | Midodrine Hcl | 25 | 16 |
| Ozempic | Semaglutide | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Folic Acid | Folic Acid | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 23 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | 16 |
| Irbesartan | Irbesartan | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | 11 |
| Ramipril | Ramipril | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Mresvia | Rsv Vaccine, Pref, Mrna/Pf | 20 | 19 |
| Pregabalin | Pregabalin | 20 | 11 |
| Silodosin | Silodosin | 20 | suppressed |
| Meropenem | Meropenem | 19 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Eplerenone | Eplerenone | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | 15 |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 18 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 17 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | 13 |
| Farxiga | Dapagliflozin Propanediol | 16 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Rexulti | Brexpiprazole | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 15 | 12 |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Acetazolamide | Acetazolamide | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Nyamyc | Nystatin | 14 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 14 | 11 |
| Solu-Medrol | Methylprednisolone Sod Succ/Pf | 14 | suppressed |
| Aranesp | Darbepoetin Alfa In Polysorbat | 13 | suppressed |
| Budesonide | Budesonide | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Clozapine | Clozapine | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 11 | 11 |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $584.85 · 28 records | Novo Nordisk Inc | AIRSUPRA, ARISTADA, Briviact, CAPLYTA, Cologuard Collection Kit, FUROSCIX, KRYSTEXXA, LYBALVI, NUZYRA, Ozempic, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TZIELD, UBRELVY, Wegovy, XHANCE, ZENPEP | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error